Navigation Links
Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
Date:12/20/2007

ting, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.

Contact:

For Indevus

Michael W. Rogers Brooke D. Wagner

Executive Vice President and CFO VP, Corporate Communications

(781) 861-8444 (781) 402-3410


'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
6. Bayer CropSciences Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... SAN FRANCISCO, Calif., Aug. 27 Poniard,Pharmaceuticals, Inc. ... oncology, today announced that Jerry McMahon, Ph.D., chairman ... September during which he,will provide a corporate overview, ... picoplatin, the Company,s lead product candidate., -- ...
... and MILPITAS, California, August 27, Peakdale Molecular ... chemistry services to the pharmaceutical and,biotechnology industry, ... unique,and cost-effective provider of products and systems ... of AssayReady4U(TM)., AssayReady4U(TM) is an online ...
... INDIANAPOLIS, Aug. 26 Amylin,Pharmaceuticals, Inc. (Nasdaq: AMLN ... ),in a conference call today provided context and additional ... Administration (FDA),update to a prior alert for BYETTA(R) (exenatide) ... cases referenced,in the alert, as well as others, and ...
Cached Biology Technology:Poniard Pharmaceuticals Announces Upcoming Conference Participation 2Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC 2Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6
(Date:4/17/2014)... KAN. A Kansas State University engineer has ... and remotely detects improvised explosive devices. The same ... William Dunn, the Steven M. and Kay L. ... mechanical and nuclear engineering, and his research team ... hidden underground or in car trunks. The distance ...
(Date:4/17/2014)... professor Rajendra Singh Thursday as a "Champion of ... solar deployment in the residential, commercial and industrial ... of Electrical and Computer Engineering and director of ... local hero leading the charge across the country ... power and driving policy changes at the local ...
(Date:4/17/2014)... the Amazon help create tinderbox conditions for wildfires ... forest loss during drought years, according to a ... in the Amazon could reach a "tipping point" ... to large-scale loss of trees, making recovery more ... Penn State. , "We documented one of the ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2White House honors Clemson professor as 'Champion of Change' for solar deployment 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3
... could also be giving us bad breath, according to research ... Medical Microbiology . For the first time, scientists have found ... who are not showing signs of stomach disease. The ... some of which can cause disease. Helicobacter pylori ...
... set of proteins known as cannabinoid receptors, which ... body also has chemicals known as endocannabinoids that ... (AEA) and 2-arachidonoylglycerol (2-AG). These natural components of ... efforts to develop new treatments not only for ...
... Buenos Aires, Argentina Current research suggests that melatonin ... disease. The related report by Sande et al., "Therapeutic ... December issue of The American Journal of Pathology ... pain in their eyes, and their vision rapidly deteriorates. ...
Cached Biology News:Stomach ulcer bug causes bad breath 2Scripps research team defines new painkilling chemical pathway 2Melatonin may save eyesight in inflammatory disease 2
Chicken polyclonal to ADI1 ( Abpromise for all tested applications). Antigen: Full length native protein (purified), corresponding to amino acids 1-179 of Human ADI1. Entrez GeneID: 55256 ...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Request Info...
Biology Products: